Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

RCT (n=97) found extended therapy with biannual rituximab infusions over 18 months was associated with significantly higher relapse-free survival vs. standard maintenance therapy alone (96% vs. 74% at month 28; absolute difference 22%, HR 7.5, p= 0.008).

Source:

Annals of Internal Medicine